AGENDA

Enclosure

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

5. Appraisal 1: Full Submission (WPAS)
   Eribulin mesilate (Halaven®) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments

6. Chairman’s report (verbal update)

7. Appraisal 2: Limited Submission
   Ursodeoxycholic acid (Ursofalk®) for the treatment of hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years

Date of next meeting: 18th May 2016 in Cardiff